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Abstract: 
Introduction: Glucose and lipid metabolism are inter related phenomenon in the human body. The number of people 
with T2DM is spiking worldwide, thus efficient management is required to improve the quality of life of diabetics. 
Objectives of the study: The main objective of the study is to analyze the Effect of Levocarnitine on Muscle Glycogen 
Content in Type 2 Diabetic patients in Pakistan. Material and methods: This case control study was conducted at 
Central Park Medical College during January 2017 to June 2017. Serum creatine phosphorkinase (CPK) levels were 
measured to exclude skeletal muscle disorder. There were 100 diabetic patients which were selected for this study. 
For this study we analyze the effect of levocarnitine on muscle glycogen content in type 2 diabetic patients. The data 
was collected through a detailed blood biochemical analysis. Fasting glucose levels were measured for further 
analysis. Results: Statistical analysis showed significant (p <0.001) increase in weight (268.40 ± 14.65 gm), fasting 
serum plasma glucose level (404.05 ± 59.65 mg/dl), fasting serum TG (132.17 ± 6.25mg/dl), fasting serum HDL (62.28 
± 1.25mg/dl) and TG:HDL ratio (2.12) due to high fat diet. The serum free carnitine was measured by terminal 
sampling and glycogen content of the EDL muscle of both groups were calculated. An increase in glycogen content 
was observed in in diabetic group (82.55±10.30 mg/100 gm muscle). Conclusion: It is concluded that Levo carnitine 
increases the glucose uptake by the skeletal muscle and hence improves the skeletal muscle glycogen stores in type 2 
diabetes mellitus. 
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INTRODUCTION: 
Glucose and lipid metabolism are inter related 
phenomenon in the human body. The number of 
people with T2DM is spiking worldwide, thus 
efficient management is required to improve the 
quality of life of diabetics. Initial management of 
T2DM consists of weight reduction, regular exercise 
and controlled diet. Exercise plays a dominant role in 
controlling hyperglycemia by way of increase in 
peripheral insulin sensitivity, strengthening insulin 
bonding and minimizing obesity [1]. 
  
Both glucose and free fatty acids (FFA) are consumed 
by skeletal muscles as sources of fuel for energy 
production. During the fasting state, FFAs provide 
major source of energy production, as skeletal muscle 
glucose uptake is considerably low [2]. After uptake 
of glucose, insulin secretion from the beta cells of 
pancreas is stimulated leading which lowers the rate of 
lipolysis leading to a reduction in plasma FFA levels. 
Simultaneously, there is a rise in the rate of glucose 
oxidation in muscle [3]. This transition from fatty acid 
oxidation to glucose oxidation is called metabolic 
flexibility. After transfer of glucose into the muscle 
cells through of GLUT-4 transporter (glucose 
transporter 4), it is phosphorylated by hexokinase, and 
then either oxidized by glycolytic pathway or stored as 
glycogen [4]. As the insulin levels rise, glycogen 
synthesis rate also improves, i.e; about 70% of glucose 
is converted to glycogen [5]. 
 
L-carnitine is the available form of carnitine present in 
the body and in food. Animal products such as meat, 
milk, poultry and fish are rich in L-carnitine. 
Levocarnitine is a synthetic form of carnitine, 
available in oral as well as injectable forms [6]. Levo 
carnitine has been used in various diseases like 
cardiomyopathies, metabolic nerve diseases, senile 
dementia, HIV infection, tuberculosis, myopathies, 
renal failure and anemia [7]. 
 
Objectives of the study 
The main objective of the study is to analyze the Effect 
of Levocarnitine on Muscle Glycogen Content in Type 
2 Diabetic patients in Pakistan. 
  
MATERIAL AND METHODS: 
This case control study was conducted at Central Park 
Medical College during January 2017 to June 2017. 
Serum creatine phosphorkinase (CPK) levels were 
measured to exclude skeletal muscle disorder. There 
were 100 diabetic patients which were selected for this 
study. For this study we analyze the effect of 
levocarnitine on muscle glycogen content in type 2 
diabetic patients. The data was collected through a 
detailed blood biochemical analysis. Fasting glucose 
levels were measured for further analysis. 
 
Statistical analysis 
Data was analysed using SPSS 17. Mean and standard 
deviation were calculated for all values. Statistical 
significance of difference between the subgroups was 
determined by applying independent samples t-test. 
(p≤0.05 was considered significant). 
 
RESULTS: 
Statistical analysis showed significant (p <0.001) 
increase in weight (268.40 ± 14.65 gm), fasting serum 
plasma glucose level ( 404.05 ± 59.65 mg/dl), fasting 
serum TG (132.17 ± 6.25mg/dl), fasting serum HDL 
(62.28 ± 1.25mg/dl) and TG:HDL ratio (2.12) due to  
high fat diet. The serum free carnitine was measured 
by terminal sampling and glycogen content of the EDL 
muscle of both groups were calculated. An increase in 
glycogen content was observed in in diabetic group 
(82.55±10.30 mg/100 gm muscle).  
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Table 01: Serum free carnitine levels and muscle glycogen content of groups 
 
 
Variables 
 
Group I 
 
 (Diabetic) 
 n = 15 
 
Group II   
(Carnitine)  
n = 15 
 
 
Group I v/s II 
  
 
 
Carnitine levels 
(nmol/µl) 
 
 
0.109 ± 0.014 
 
0.312 ± 0.158 
 
 
p  <  0.001 
 
Glycogen content (mg per 100gm muscle) 
 
82.55 ± 10.30       
 
124.20 ± 17.78       
 
 
p  <  0.001 
 
 
All values are expressed as Mean ± SD 
 
DISCUSSION: 
Our observation showed that levo-carnitine increased 
the muscle glycogen content in T2DM. The fast twitch 
muscles (type II) were used because they have 
comparatively more glycogen stores than the slow 
twitch muscle. Also, the lower levels of muscle 
glycogen in T2DM has been observed to be higher in 
type II muscle fibers as compared to type I muscle 
fibers [8]. Muscle glycogen is an important fuel for 
moderate to severe intensity exercise, and exercise is 
one of the initial regimens for management of T2DM. 
Studies have shown that l-carnitine increases insulin 
sensitivity in T2DM, thereby improving glucose 
uptake by all tissues up to 8% of the basal glucose 
uptake level. Carnitine has also been shown to 
improve PDH activity, resulting in reduction of 
plasma and skeletal muscle lactate levels by improving 
glucose oxidation. Studies have also proved that 
increase in plasma carnitine levels results in increased 
storage of skeletal muscle glycogen [9].  In present 
study, l- carnitine administration has shown to raise 
the plasma free carnitine levels 3 fold as compared to 
the diabetic group [10]. Studies by Tamamogullari et 
al. had determined the levels of total, free and 
esterified carnitines in humans and observed that the 
levels of these carnitines were decreased in diabetic 
patients. Free carnitine levels were found to be lower 
in diabetics while esterified carnitines were found 
higher in diabetics [11].  
 
CONCLUSION: 
It is concluded that Levo carnitine increases the 
glucose uptake by the skeletal muscle and hence 
improves the skeletal muscle glycogen stores in type 2 
diabetes mellitus. 
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